Imunon (IMNN) Net Margin (2017 - 2022)
Imunon's (IMNN) quarterly Net Margin came in at 8860.63% in Q4 2022, down 2139834.0% YoY from N/an in Q4 2021, and down 79.45% on a QoQ basis from 4937.63% in Q3 2022.
Imunon (IMNN) Net Margin (2017 - 2022) Analysis & Trends
Imunon (IMNN) has 6 years of Net Margin data on file, last reported at 8860.63% in Q4 2022.
- Quarterly Net Margin fell 2139834.0% year-over-year to 8860.63% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 5863.11% (down 578981.0% YoY) and the FY2022 annual result came in at 7179.65%, down 302580.0% from the prior year.
- Net Margin fell to 8860.63% in Q4 2022, from 4937.63% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 22642.18% in Q4 2019 to a low of 8860.63% in Q4 2022.
- A 5-year average of 1949.8% and a median of 4125.6% in 2019 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2019 — Net Margin soared 1825772 bps — and 2020, when it plunged 2617673 bps.
- Tracing IMNN's Net Margin over 5 years: stood at 4384.46% in 2018, then jumped by 416 bps to 22642.18% in 2019, then plunged by 116 bps to 3534.55% in 2020, then surged by 455 bps to 12537.7% in 2021, then tumbled by 171 bps to 8860.63% in 2022.
- The last three Net Margin figures came in at 8860.63% (Q4 2022), 4937.63% (Q3 2022), and 4870.63% (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -8,860.63% |
| Sep 30, 2022 | -4,937.63% |
| Jun 30, 2022 | -4,870.63% |
| Mar 31, 2022 | -4,783.56% |
| Dec 31, 2021 | 12,537.70% |
| Sep 30, 2021 | -4,165.71% |
| Jun 30, 2021 | -4,234.38% |
| Mar 31, 2021 | -4,430.84% |
| Dec 31, 2020 | -3,534.55% |
| Sep 30, 2020 | -3,685.98% |
| Jun 30, 2020 | -4,071.60% |
| Mar 31, 2020 | -4,013.61% |
| Dec 31, 2019 | 22,642.18% |
| Sep 30, 2019 | -4,496.61% |
| Jun 30, 2019 | -4,620.46% |
| Mar 31, 2019 | -4,085.49% |
| Dec 31, 2018 | 4,384.46% |
| Sep 30, 2018 | -3,725.11% |
| Jun 30, 2018 | -6,584.44% |
| Mar 31, 2018 | -3,459.09% |